TY - JOUR
T1 - Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity
AU - Sharma, Surendra K.
AU - Jha, Brajesh Kumar
AU - Sharma, Abhishek
AU - Sreenivas, V.
AU - Upadhyay, Vishwanath
AU - Jaisinghani, Chandrita
AU - Singla, Rohit
AU - Mishra, Hemant Kumar
AU - Soneja, Manish
N1 - Publisher Copyright:
© 2017, Indian Council of Medical Research. All rights reserved.
PY - 2016/12
Y1 - 2016/12
N2 - Background & objectives: The N-acetyltransferase 2 (NAT2) gene encodes an enzyme which both activates and deactivates arylamine and other drugs and carcinogens. This study was aimed to investigate the role of NAT2 gene polymorphism in anti-tuberculosis drug-induced hepatotoxicity (DIH). Methods: In this prospective study, polymerase chain reaction-restriction fragment length polymorphism results for NAT2 gene were compared between 185 tuberculosis patients who did not develop DIH and 105 tuberculosis patients who developed DIH while on anti-tuberculosis drugs. Results: Frequency of slow-acetylator genotype was commonly encountered and was not significantly different between DIH (82.8%) and non-DIH (77.2%) patients. However, the genotypic distribution of variant NAT2*5/*7 amongst slow-acetylator genotypes was significantly higher in DIH (56%) group as compared to non-DIH (39%) group (odds ratio 2.02; P=0.006). Interpretation & conclusions: The present study demonstrated no association between NAT2 genotype and DIH in the north Indian patients with tuberculosis.
AB - Background & objectives: The N-acetyltransferase 2 (NAT2) gene encodes an enzyme which both activates and deactivates arylamine and other drugs and carcinogens. This study was aimed to investigate the role of NAT2 gene polymorphism in anti-tuberculosis drug-induced hepatotoxicity (DIH). Methods: In this prospective study, polymerase chain reaction-restriction fragment length polymorphism results for NAT2 gene were compared between 185 tuberculosis patients who did not develop DIH and 105 tuberculosis patients who developed DIH while on anti-tuberculosis drugs. Results: Frequency of slow-acetylator genotype was commonly encountered and was not significantly different between DIH (82.8%) and non-DIH (77.2%) patients. However, the genotypic distribution of variant NAT2*5/*7 amongst slow-acetylator genotypes was significantly higher in DIH (56%) group as compared to non-DIH (39%) group (odds ratio 2.02; P=0.006). Interpretation & conclusions: The present study demonstrated no association between NAT2 genotype and DIH in the north Indian patients with tuberculosis.
KW - Drug-induced hepatotoxicity
KW - Genetic polymorphism
KW - N-acetyltransferase 2
KW - Polymerase chain reaction
KW - Rapid acetylator
KW - Restriction fragment length polymorphism
KW - Slow acetylator
UR - http://www.scopus.com/inward/record.url?scp=85019003072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019003072&partnerID=8YFLogxK
U2 - 10.4103/ijmr.IJMR_684_14
DO - 10.4103/ijmr.IJMR_684_14
M3 - Article
C2 - 28474630
AN - SCOPUS:85019003072
SN - 0971-5916
VL - 144
SP - 924
EP - 928
JO - Indian Journal of Medical Research
JF - Indian Journal of Medical Research
IS - DECEMBER
ER -
